Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, ... Next earnings are expected to be released in 28 days. Professional Analyst Ratings for Eli Lilly.

Lilly's forward price-to-earnings (P/E) ratio currently tops 35, which is more than twice the average of 15.8 for the healthcare industry. 3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow ...

Eli Lilly down 19% in May, worst month since 2009. Underperformed S&P 500 by 24%, worst since August 2000. June shows promise, historically Lilly’s strongest month. A new wave of value and ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. ... and earnings per share (EPS) of $20.17–$21.67 (on a GAAP basis), for a price to earnings ratio of ~37x. ...

Eli Lilly (LLY 1.34%) has been a growth beast over the years and is now easily the most valuable healthcare company in the world, with a market cap of more than $650 billion.